Achalasia Market By Treatment Type (Drug Therapy (Calcium Channel Blockers, Nitrates, Botulinum Toxin), Endoscopic Therapy (Balloon Dilation, POEM, Botox Injections), Surgical Therapy (Heller Myotomy, Laparoscopic Surgery), Lifestyle Modifications); By Diagnosis Type (Esophageal Manometry, Endoscopy, Imaging (Barium Swallow Test)); By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers); By Geography, Segment revenue estimation, Forecast, 2024–2032.

The achalasia market size was USD 1.3 billion in 2023 and is expected to reach USD 2.4 billion by 2030 at a CAGR of 8.5% during the forecast period from 2024 to 2030. The increase in the incidence rate, improving affordability for endoscopic techniques, and availability of new techniques like POEM and Injection of botulinum toxin are responsible for the growth of this market.

 

Achalasia is a relatively rare esophagus disease that impairs its motility and the ability to move food to the stomach. This condition results from damage to oesophageal nerves and failure of the lower oesophageal sphincter to open as required. The global market for achalasia treatment continuously expands as patients become more aware of this disease and modern diagnostic and treatments.

 

It is fundamental to meet the needs of patients with hard-to-manage symptoms and patients who prefer alternatives that do not require complicated procedures. This is supported by the various uses in various healthcare facilities, such as specialty hospitals and clinics, besides embracing research and development projects to enhance the QOL of the affected patients.

 

Market Drivers

Rising Prevalence of Achalasia: This includes the rise in the frequency of occurrence of this disease across the world. The global prevalence of achalasia, estimated based on available data, is 10 per 100,000 populations, while the incidence rates range between 1–2/100,000 population per year, according to the meta-analysis featured in The Lancet Gastroenterology & Hepatology. Market demand has been growing due to increased and earlier diagnosis and treatment by both the patients themselves and other healthcare workers.

 

Advancements in Diagnostic and Therapeutic Technologies: Other advances in imaging, including high-resolution manometry (HRM) and endoscopic ultrasound, have dramatically changed the approach to diagnosing achalasia. On the treatment front, there are making new approaches like POEM. For instance, according to Cleveland Clinic, its POEM procedures increased by 15% in 2022 from the previous year due to procedures efficiency and being less invasive.

 

Growing Geriatric Population: Achalasia is prevalent in old age patients and the global ageing population has posed a tremendous influence on market growth. For instance, according to the United Nations, the world’s population of people aged 60 years and above will in the next 34 years more than double, creating a larger base of possible achalasia patients.

 

Increased Healthcare Expenditure: Growing health care expenditures in other parts of the world has made it possible to acquire these enhanced healthcare services. The World Health Organization WHO announced that, across the low and middle-income countries, healthcare spending in this sector has increased by at least 6% per year in the past one decade and therefore the diagnostics and therapies of the rare diseases like achalasia have improved.

 

Market Opportunities

Emerging Markets in Asia-Pacific: The Asia-Pacific region is expected to showcase a higher degree of growth because of advances in healthcare facilities and increasing awareness of achalasia. For example, India and China mentioned an increased use of sophisticated diagnostic technologies in tier-three hospitals that stimulated the demand for treatments.

 

Innovative Treatments and Partnerships: Robotic assisted surgeries and targeted drug therapies are the primary trends that the company is poised to capitalize on and the market poised to pull. Players like Medtronic currently in partnership with University of Texas Medical Branch for minimally invasive technologies put a lot into advancing the market.

 

Telemedicine and Remote Monitoring: Telemedicine solutions enable patients to get an audience with specialists. Campaigns established by the Mayo Clinic involving virtual consultation of gastrointestinal diseases have played a crucial role in covering aging to the needy.

 

Market Restraints

High Costs of Advanced Treatments: Surgical procedures such as POEM might be costly, reaching $10,000 to $20,000 per procedure, making them out of reach for patients from regions with low economic productivity.

 

Lack of Awareness in Rural Areas: The education and awareness levels of professionals and patients in the developed world are relatively high but similar to other LDMs, the scarcity of a trained workforce is a critical issue.

 

Complications and Recurrence Risks: Certain therapies, such as pneumatic dilation, have side effects that could harm the patient, such as esophageal perforation or reoccurrence of symptoms. This would make patients reluctant to embark on such therapy.

 

Market Segmentation

• By Treatment Type:

  • Drug Therapy (Calcium Channel Blockers, Nitrates, Botulinum Toxin)

  • Endoscopic Therapy (Balloon Dilation, POEM, Botox Injections)

  • Surgical Therapy (Heller Myotomy, Laparoscopic Surgery)

  • Lifestyle Modifications

 

• By Diagnosis Type:

  • Esophageal Manometry

  • Endoscopy

  • Imaging (Barium Swallow Test)

 

• By End User:

  • Hospitals

  • Specialty Clinics

  • Ambulatory Surgical Centers

 

• By Region:

  • North America

  • Europe

  • Asia-Pacific

  • Latin America

  • Middle East & Africa

 

Segment Analysis

Leading Treatment Segment: Endoscopic Therapy

The most active segment of that market is the endoscopic therapy, boosted by the POEM application. The symptoms of this condition have also been treated with very good results with this method, with one research revealing that it has an overall success of 90 percent. Some of the benefits include shorter length of hospital stay and, therefore, shorter recovery time and reduced chances of contracting complications.

 

Regional Analysis

North America is anticipated to hold the largest share of the achalasia treatment market, contributing nearly 45% of the international revenue in 2023. The region's high-quality healthcare facilities, well-informed consumers, and favorable reimbursement policies make it a leader.

 

Europe is influenced most by Germany and the UK, as these countries have effective health insurance. In 2022, the NHS in the United Kingdom authorized funding for POEM procedures to improve patients’ access to such complex technologies.

 

Key Players

• Medtronic

• Boston Scientific Corporation

• Olympus Corporation

• Cook Medical

• Johnson & Johnson

• Abbott Laboratories

• Takeda Pharmaceutical Company Limited

• Intersurgical Ltd.

• Pentax Medical

• Torax Medical

 

Future Outlook

“The treatment of achalasia is expected to continue to grow technologically and in the eyeballs of the patients in the future, and this is expected to create a healthy market for the industry.” Robotically assisted surgeries alongside accurate diagnostic procedures will define new treatment plans. Existing and new entrants are more inclined toward green and affordable solutions, and telemedicine solutions will continue to create propositions for unserved populations.

 

Thus, by 2030, the market is likely to experience increased use of innovative treatments with more positive results for patients and increased availability worldwide. Under the future simulation of prolonged RD investments, the market for achalasia treatment will become one of the main targets to enhance the quality of life for patients with this disorder globally.